• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Feasibility of cabazitaxel in octogenarian prostate cancer patients
CONCLUSIONS: Octogenarian patients can be treated with cabazitaxel with reduced doses or alternative schedules that are associated with less toxicity and fewer treatment interruptions. Comprehensive geriatric assessment could facilitate more appropriate patient selection.PMID:37448615 | PMC:PMC10337820 | DOI:10.1097/CU9.0000000000000081
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: Paolo Tralongo Sebastiano Bordonaro Giuseppe Di Lorenzo Ugo De Giorgi Nicol ò Borsellino Gaetano Facchini Sabrina Rossetti Giuseppe Fornarini Vito Longo Antonino Carmelo Tralongo Francesca Caspani Massimiliano Spada Nicola Calvani Paolo Carlini Source Type: research

Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients
CONCLUSIONS: According to our analysis, the risk factors obesity and prevalence of CTCs are not associated and may represent independent prognostic factors.PMID:37336651 | DOI:10.1016/j.clbc.2023.05.011
Source: Clinical Genitourinary Cancer - June 19, 2023 Category: Cancer & Oncology Authors: Marie Tzschaschel Thomas W P Friedl Fabienne Schochter Sabine Sch ütze Arkadius Polasik Tanja Fehm Klaus Pantel Christian Schindlbeck Andreas Schneeweiss J örg Schreier Hans Tesch Ralf Lorenz Viktoria Aivazova-Fuchs Lothar H äberle Peter Fasching Wolfg Source Type: research

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
CONCLUSION: Real-world mCRPC treatment patterns largely reflected national guidelines. It is expected that guidelines and treatment patterns will change with the development of new treatment options.PMID:35316501 | DOI:10.1007/s12325-022-02073-w
Source: Adv Data - March 22, 2022 Category: Epidemiology Authors: Andrea Leith Jeri Kim Amanda Ribbands Emily Clayton Lingfeng Yang Sameer R Ghate Source Type: research

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
Conclusions: Nivolumab and pembrolizumab have promising outcomes with tolerable AEs and drug-related deaths in patients with relapsed or refractory lymphoma. Pembrolizumab caused less any grade AEs like fatigue and rash than nivolumab. Patients with HL got better response than NHL. Introduction Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor mainly expressed on activated T cells, natural killer cells, and B cells (Ishida et al., 1992). The PD-L1 and PD-L2 are its known ligands, which interact with PD-1 on T cells and prevent T-cell activation and proliferation. PD-L1 is expressed on macropha...
Source: Frontiers in Pharmacology - April 30, 2019 Category: Drugs & Pharmacology Source Type: research

DNMT Inhibitors Increase Methylation in the Cancer Genome
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Conclusions MDSC are major players in the immunosuppressive scenario in cancer, thanks to their phenotype heterogeneity and critical interaction with several innate immune cells, thus representing a crucial target in oncology. Here we reviewed the interactions of MDSCs with NK cells. The contribution of key cytokines, chemokines and mediators active in this process have been discussed. We also described the contribution of MDSC on angiogenesis directly or indirectly through interactions with NK and immunosuppressive activities. A parallel of the cancer associated to the decidual counterpart of these cells is discussed, a...
Source: Frontiers in Immunology - April 17, 2019 Category: Allergy & Immunology Source Type: research

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
Conclusion and Relevance: Checkpoint inhibitors plus chemotherapy compared with chemotherapy, are associated with significantly prolonged OS and PFS in first-line therapy in NSCLC. In the low PDL1 subgroups the benefit was statistically significant only in the pembrolizumab backbone trials. The findings of this meta-analysis could assist in the design and interpretation of future trials and in economic analyses. Introduction Lung cancer is the leading cause of cancer death worldwide. Non-small-cell lung cancer (NSCLC) accounts for almost 85% of all cases (1). The prognosis of NSCLC patients remains quite unsatisfacto...
Source: Frontiers in Oncology - April 15, 2019 Category: Cancer & Oncology Source Type: research